The Leaked Technique For Ramoplanin Spotted

428/A/09; GRS 768/B/13), and the Intensification of Research Program. Competing interests: None declared. Patient consent: Obtained. Ethics approval: An independent ethics committee of health area of Salamanca (Spain). Provenance and peer review: Not commissioned; externally peer reviewed. Data sharing statement: No additional data are available.""Chronic obstructive pulmonary disease (COPD) is an increasing burden on healthcare systems globally.1 Along with the persistent and progressive airflow limitation that characterises COPD,2 exacerbations of COPD significantly impair patients' lives and further increase the burden on healthcare services.2 3 Moderate-to-severe find more exacerbations are significant events associated with poor patient prognosis, including worse quality of life, more rapid disease progression and, for severe events, increased mortality.2 3 Addition of an inhaled corticosteroid (ICS) to bronchodilator maintenance therapy has been shown to decrease exacerbations among patients with COPD4�C10 and, BGB324 ic50 as a result, the current Global Initiative for Chronic Lung Disease (GOLD) guidelines recommend a fixed-dose combination therapy of ICS/long-acting ��2 agonist (LABA) for patients at risk of frequent exacerbations (ie, two or more per year).2 The identification of patients who may respond more favourably to one treatment option versus another is an important consideration for patients and healthcare providers, allowing for optimal patient management and evaluation of risks versus benefits when allocating limited healthcare resources.5 6 11 Cluster analysis is one method of identifying groups of patients who are more likely to benefit from one treatment versus another based on clinical characteristics, and this analysis can be particularly useful in complex, heterogeneous diseases such as COPD.12 Cluster analysis has previously been used to identify patients who had greater exacerbation reduction with an LABA (salmeterol (SAL)) in combination with an ICS, fluticasone Ramoplanin propionate (SAL/fluticasone combination, SFC) compared with SAL alone.13 Clusters of patients receiving diuretics and those not receiving diuretics but with a baseline bronchodilator reversibility of ��12% were found to have significantly greater reductions in exacerbations when treated with SFC versus SAL, based on clinical trial data comparing treatment with SFC versus SAL. No significant differences were found between the treatments in a third cluster of patients not receiving diuretics and with baseline bronchodilator reversibility of